Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.63

52W Range

$0.50 - $9.75

50D Avg

$0.98

200D Avg

$1.76

Market Cap

$1.09M

Avg Vol (3M)

$1.05M

Beta

0.51

Div Yield

-

CYCC Company Profile


Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

12

IPO Date

Mar 16, 2004

Website

CYCC Performance


CYCC Financial Summary


Dec 23Dec 22Dec 21
Revenue$420.00K--
Operating Income$-30.30M$-27.66M$-22.94M
Net Income$-22.55M$-21.20M$-18.89M
EBITDA$-30.27M$-27.89M$-22.98M
Basic EPS$-26.51$-1.88$-2.12
Diluted EPS$-26.51$-1.88$-2.12

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 14, 24 | 8:18 PM
Q1 24May 14, 24 | 12:00 AM
Q4 23Mar 19, 24 | 6:09 PM

Peer Comparison


TickerCompany
CYTCyteir Therapeutics, Inc.
NXTCNextCure, Inc.
PULMPulmatrix, Inc.
IKNAIkena Oncology, Inc.
EWTXEdgewise Therapeutics, Inc.
CTMXCytomX Therapeutics, Inc.
SPROSpero Therapeutics, Inc.
AKTXAkari Therapeutics, Plc
CNTBConnect Biopharma Holdings Limited
ASMBAssembly Biosciences, Inc.
RZLTRezolute, Inc.
TPSTTempest Therapeutics, Inc.
MBRXMoleculin Biotech, Inc.
OVIDOvid Therapeutics Inc.
PTIXProtagenic Therapeutics, Inc.
NLTXNeurogene Inc.
CBIOGyre Therapeutics, Inc.
ELYMEliem Therapeutics, Inc.